Ca-AKG for muscle, frailty and sarcopenia
Ca-AKG for muscle and frailty: mouse frailty and sarcopenia data, muscle stem-cell biology, diabetic muscle fibrosis, OXGR1 signaling and the limited human evidence.
Evidence library 24 analyses
A research hub for calcium alpha-ketoglutarate (Ca-AKG): longevity biology, human evidence, dosing, formulations and safety.
Complete library
Browse every published guide, review and evidence update in this topic.
Ca-AKG for muscle and frailty: mouse frailty and sarcopenia data, muscle stem-cell biology, diabetic muscle fibrosis, OXGR1 signaling and the limited human evidence.
Ca-AKG and grey hair: one mouse study found more melanocyte-containing follicles and fur repigmentation, but the finding remains unreplicated and has never been tested in humans.
Ca-AKG and bone health: the randomized osteopenia trial, CTX reduction, dose interpretation, osteoclast and osteoblast mechanisms, and newer osteoporosis models.
Ca-AKG and biological age: the 2021 Rejuvant result, the 4,260-person Pabis 2026 cohort, the non-significant adjusted longitudinal signal, and what ABLE has—and has not—shown.
Ca-AKG stacking with NMN, fisetin, Urolithin A and AAKG: complementary mechanisms can justify research, but no combination-specific human longevity benefit has been demonstrated.
Ca-AKG and autophagy: AKG activates autophagy in some worm, fly, brain-slice and immune-cell models but inhibits it in other systems. Human oral autophagic-flux data are absent.
When to take Ca-AKG: no study proves a best time of day. What human protocols actually used, what food timing does not establish, and when calcium–medication spacing matters.
Ca-AKG dosage reviewed against the human evidence: why 1 g/day is the common modern research dose, why it is not a proven optimum, and what higher-dose studies actually...
AKG forms compared by evidence: Ca-AKG, delayed-release Ca-AKG, free AKG, AAKG, OAKG and other salts—with form-specific human data kept separate.